Cullinan Therapeutics Inc ASH 2025 Analyst and Investor Event Transcript - Thomson StreetEvents

Cullinan Therapeutics Inc ASH 2025 Analyst and Investor Event Transcript

Cullinan Therapeutics Inc ASH 2025 Analyst and Investor Event Transcript - Thomson StreetEvents
Cullinan Therapeutics Inc ASH 2025 Analyst and Investor Event Transcript
Published Dec 09, 2025
17 pages (11736 words) — Published Dec 09, 2025
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Transcript of CGEM.OQ conference call or presentation 9-Dec-25 1:00am GMT

  
Brief Excerpt:

...Good evening, everyone. Thanks for coming as we look forward to discussing the compelling initial results for CLN-049 that were presented at ASH today and also look forward to the promise of CLN-049 for patients with AML. So our disclosure slide. So as outlined in the slide, during this event, management will be making certain forward-looking statements. Please consult the risk factors discussed in our SEC filings for additional uncertainties that may cause the actual results to differ. All right. Glad to get that one out of the way. Okay. So turning to this evening. I'm very pleased to welcome Dr. Jeff Jones, our Chief Medical Officer, and we're especially pleased to welcome Dr. David Sallman from the Moffitt Cancer Center, where he's associate member, a myeloid section head, also the research institute. And now not only is Dr. Sallman, a leading investigator in our study, he's also a leading researcher in the field of TP53-mutated AML and MDS, which you'll see is very, very important...

  
Report Type:

Transcript

Source:
Thomson StreetEvents
Company:
Cullinan Therapeutics Inc
Ticker
CGEM.OQ
Time
1:00am GMT
Format:
PDF Adobe Acrobat
Buy Now

The following is excerpted from the question-and-answer section of the transcript.

(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)

Question: Marc Frahm - Cowen and Company LLC - Analyst : Thanks for that, and congrats on the data. It's Marc Frahm from TD Cowen. Maybe for Dr. Sallman, you really elegantly talked about the true unmet need in the TP53 positive. But can you maybe just talk through a little bit of the unmet need on the other side of the bar on the TP53 negatives? And where what you would be encouraged by -- as the experience gets bigger on that side of the setting as well? And then maybe for the company as well, just in AML, I mean, certainly relapsed/refractory first line like you laid out, but another big opportunity often is the maintenance setting. Just what's the -- is there a plan there at all? And maybe this is also a little bit for Dr. Sallman, just the AE profile you're seeing, how amenable that may or may not be to that setting?

Table Of Contents

Cullinan Therapeutics Inc at Morgan Stanley Global Healthcare Conference Transcript – 2025-09-10 – US$ 54.00 – Edited Transcript of CGEM.OQ presentation 10-Sep-25 12:30pm GMT

Cullinan Therapeutics Inc Annual Shareholders Meeting Transcript – 2025-06-12 – US$ 54.00 – Edited Transcript of CGEM.OQ shareholder or annual meeting 12-Jun-25 2:00pm GMT

Cullinan Therapeutics Inc To Provide Corporate Update Transcript – 2025-06-04 – US$ 54.00 – Edited Transcript of CGEM.OQ conference call or presentation 4-Jun-25 8:30pm GMT

Cullinan Therapeutics Inc ASCO Investor Event Transcript – 2025-06-01 – US$ 54.00 – Edited Transcript of CGEM.OQ conference call or presentation 1-Jun-25 11:30pm GMT

Cullinan Therapeutics Inc at TD Cowen Healthcare Conference Transcript – 2025-03-04 – US$ 54.00 – Edited Transcript of CGEM.OQ presentation 4-Mar-25 4:10pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "Cullinan Therapeutics Inc ASH 2025 Analyst and Investor Event Transcript" Dec 09, 2025. Alacra Store. Nov 06, 2026. <http://www.alacrastore.com/thomson-streetevents-transcripts/Cullinan-Therapeutics-Inc-ASH-2025-Analyst-and-Investor-Event-T16556513>
  
APA:
Thomson StreetEvents. (2025). Cullinan Therapeutics Inc ASH 2025 Analyst and Investor Event Transcript Dec 09, 2025. New York, NY: Alacra Store. Retrieved Nov 06, 2026 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Cullinan-Therapeutics-Inc-ASH-2025-Analyst-and-Investor-Event-T16556513>
  
US$ 54.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.